Injection under the skin for moderate to severe Alzheimer’s
Part of Brain & nervous system, Mental health clinical trials.
This Phase 3 trial tests GV1001 given as a skin injection to see if it can slow worsening symptoms in people with moderate to severe Alzheimer’s disease. You may be able to join if you’re in a specific age range, taking stable Alzheimer’s medicines, and meet screening brain-test and memory-score requirements.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be age 55 to 85
- Have Alzheimer’s-related dementia confirmed by specialist criteria and symptoms
- Score 19 or less on the mini-mental test (K-MMSE) and be in moderate-to-severe stage on the global deterioration scale (GDS grade 5–6)
- Have brain scans (CT/MRI) showing no other cause of dementia within the last 12 months
- Be on a stable dose of donepezil (alone) or donepezil plus memantine for at least 3 months before screening
- Have a caregiver who can attend visits, help with testing, and sign consent in writing
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 4 trial tests whether a medicine called sodium oligomannate (GV-971) is safe and effective for people with mild to moderate Alzheimer’s disease. It may help slow or improve memory and thinking symptoms while carefully tracking side effects.
This Phase 2 study tests whether sargramostim (a GM-CSF related medicine) is safe and can slow or improve Alzheimer’s symptoms. You might be a good fit if you have mild or moderate Alzheimer’s, positive amyloid testing, and can complete frequent visits with a close caregiver who knows you well.
This early-stage trial tests whether ABBV-1758, a new drug given by injection, is safe and effective for people with Alzheimer's disease. The drug targets amyloid, a protein that builds up in the brains of people with Alzheimer's.
This trial tests a new medicine, VHB937, in people with early Alzheimer's (mild cognitive impairment or mild dementia). The goal is to see if it can slow down memory loss and thinking problems.
This trial tests a new immune cell therapy (SNK01) for people with moderate Alzheimer's disease. The goal is to see if it can slow down memory and thinking decline.
This trial tests an investigational injection for people in the early stages of Alzheimer's. It aims to see if the drug can safely slow down memory loss and brain changes.
Hear when a new Moderate to Severe Alzheimer's Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.